Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Seretide vs. other ICS/LABAs
Find out about price, small particles and paediatric license
How well controlled are your asthma patients?
The ACT (Asthma Control Test) is a validated tool that assesses asthma control across 5 domains1
Asthma symptom control
With proactive regular dosing, Seretide achieves and maintains well controlled asthma2
With Seretide, 3 out of 4 patients who achieved at least well controlled asthma, remianed controlled after 1 year2
Rescue-free days
With Seretide, asthma patients shouldn’t need their rescue inhaler 6 days out of 7*3.
*Patients who were stratum 2 of the GOAL study i.e on low dose ICS, the GOAL data has been extrapolated from over one year into one week
Exacerbation rate reduction
Seretide significantly reduces the risk of severe exacerbations by 21%* compared to an ICS alone in patients with a history of exacerbations (p<0.001)4
*The absolute risk reduction compared with an ICS alone is 2%. Incidence of 8% (n=480/5834) with Seretide compared to 10% (n=597/5845) with an ICS alone.
SERETIDE EVOHALER is generally well tolerated5
After more then 100 million patient-years' exposure in asthma and COPD6, the side effect profile of Seretide is very well established (Seretide Evohaler is not licensed in COPD):
| Very common (≥1/10) |
Headache, nasopharyngitis* |
| Common (≥1/100 to <1/10) |
Candidiasis of the mouth and throat, pneumonia*, bronchitis*, hypokalaemia*, throat irritation, hoarseness/dysphonia, sinusitis*, contusions*, muscle cramps, traumatic fractures*, arthralgia, myalgia |
| Uncommon (≥1/1000 to <1/100) |
Cutaneous hypersensitivity reactions, respiratory symptoms (dyspnoea), hyperglycaemia, anxiety, sleep disorders, tremor, cataract, palpitations, tachycardia, atrial fibrillation, angina pectoris |
| Rare (≥1/10,000 to <1/1000) |
Oesophageal candidiasis, angioedema (mainly facial and oropharyngeal oedema), respiratory symptoms (bronchospasm), anaphylactic reactions including anaphylactic shock, Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, behavioural changes including psychomotor hyperactivity and irritability (predominantly in children), glaucoma, cardiac arrhythmias (including supraventricular tachycardia and extrasystoles), paradoxical bronchospasm |
| Not known (frequency cannot be estimated) |
Depression, aggression (predominantly in children), blurred vision |
*Reported over 3 years in a COPD study
Supporting your patients to achieve well controlled asthma
References
- Nathan RA et al. J Allergy Clin Immunol. 2004;113:59-65
- Bateman ED et al. Am J Respir Crit Care Med 2004; 170:836-844
- Woodcock AA et al. Prim Care Respir J 2007; 16:155-161.
- Stempel DA et al. N Engl J Med 2016; 374:1822-30
- Seretide Evohaler SmPC
- GSK Data on File REF-26724
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
March 2022 | PM-GB-FPS-WCNT-210003 (V1.0)
